FDA staff shoots down Pfizer singular illness drug

<p>WASHINGTON (Reuters) – Drug reviewers on Tuesday endorsed rejecting a <span>Pfizer Inc</span> drug since a information did not infer it worked good in treating a singular <span>neurodegenerative disease</span>.</p>
<p> The <span>U.S. Food and Drug Administration staff</span> reviewed a pill, tafamidis, forward of an <span>advisory panel</span> of outward experts, that on Thursday will opinion on either to suggest it for approval. The <span>FDA</span> will make a <span>final decision</span> later, holding into comment a panel’s recommendation.</p>
<p> Tafamidis, that is already authorized in Europe underneath a name Vyndaqel, is meant to provide patrimonial amyloid polyneuropathy, a deadly condition that affects as many as 10,000 people worldwide, including about 2,500 Americans.</p>
<p> Most people with a genetic turn that is suspic...